Celecoxib CAS 169590-42-5
Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica Celecoxib (CAS: 169590-42-5) magna qualitate.Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase Celecoxib,Please contact: alvin@ruifuchem.com
| Nomen chemicum | Celecoxib |
| Synonyma | Celebrex;Celebra;Celecox;Onsenal;Solexa;SC-58635;SC 58635;YM-177;4-[5-(4-Methylphenyl) -3-(Trifluoromethyl) -1H-Pyrazol-1-yl] benzenesulfonamide;5-(4-Methylphenyl) -1-(4-Sulfamoylphenyl) 3-(Trifluoromethyl) pyrazole |
| Stock Status | In Stock, Commercial Productio |
| CAS Number | 169590-42-5 |
| Formulae hypotheticae | C17H14F3N3O2S |
| M. Pondus | 381.37 g/mol |
| Liquescens punctum | 160.0 ad 165.0℃ |
| Density | 1.43±0.10 g/cm3 |
| Aqua Solubility | Insolubilis in aqua |
| Solubilitas | Solubile in Methanol;Solutum in Ethanol |
| COA & MSDS | Praesto |
| Sample | Praesto |
| Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Items | Signa inspectionis | Proventus |
| Aspectus | Alba aut fere alba Crystallina pulveris | Obsequitur |
| Assay | 98.0~ 102.0% | 99.8% |
| Liquescens punctum | 160.0 ad 165.0℃ | 162.2℃ |
| Aquae Caroli Fischer | <0.50% | 0.11% |
| Residere in Ignition | <0.20% | 0.05% |
| Metalla gravia (Pb) | ≤20ppm | <10ppm |
| Celecoxib Related Compone A | <0.40% | <0.20% |
| Celecoxib Related Compone B | <0.10% | <0.10% |
| Impuritas individua non specificata | <0.10% | <0.10% |
| Summa immunditiae | <0.50% | 0.20% |
| Infrared Imaginis | Congruunt Structure | Obsequitur |
| 1H NMR Imaginum | Congruunt Structure | Obsequitur |
| conclusio | Productum probatum est et cum datis specificationibus obsequitur | |
Sarcina:Fluorinated Utrem, aluminium ffoyle, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Continentem arcte clausam et in loco frigido, sicco (2~8℃) reponunt et a cellis bene ventilatis ab substantiis incompossibilibus.A luce et humore protege.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.
Celecoxib
C17H14F3N3O2S 381.4
4-[5-(4-Methylphenyl) -3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide;
p.
DEFINITIO
Celecoxib continet NLT 98.0% et NMT 102.0% C17H14F3N3O2S, calculi anhydroi fundamentum.
IDENTIFICATIO
• A. ABSORPTIO INFRARED <197>: [NOTA-MODUM <197A>, <197K> vel <197M> sub infrared absorptione adhiberi potest.]
[NOTA-Si spectra consecuta differentias ostendunt, substantiam examinandae dissolve ac separatim in alcohole isopropyl alcohole Reference Latin, ad siccitatem evaporare, ac nova spectra notare.
• B. Retentionis tempus maioris apicem solutionis Sample respondet solutioni vexilliferorum, prout habetur in Assay.
TEMPTATIO
• MODO PROCEDENDI
Quiddam: 2.7 g/L potassae monobasicae phosphatae cum acido phosphorico ad pH 3.0 ± 0.2 accommodato.
Mobile phase: Methanol, acetonitrile et Buffer (3:1: 6)
Diluent: Methanol et aqua (3:1).
Solutio aptabilitas systematis: 0.5 mg/mL de USP
Celecoxib RS et 2.4 µg/mL singulae USP Celecoxib Compositae A RS et USP Celecoxib Compositae Compone B RS in Diluent.
Solutio Standard: 0.5 mg/mL USP Celecoxib RS in Diluent
Sample solutio: 0.5 mg/mL de Celecoxib in Diluent .
Systema chromatographicum
(Vide Chromatographiam <621>, Ratio idoneitatis.)
Modus: LC
Detector: UV 215 nm
Columna: 4.6-mm × 25-cm;5-µm stipare L11
Columna temperatus: 60°
Fluunt rate: 1.5 mL/min
Iniectio amplitudo: 25 µL
Currere tempus: Circa 1.5 temporibus celecoxib cacumen elution
Ratio convenientia
Exempla: Ratio idoneitatis solutionis et solutionis Standardi
Convenientia requisita
Resolutio: NLT 1.8 inter celecoxib cognata composita A et Celecoxib et NLT 1.8 inter Celecoxib et Celecoxib relata compositi B, Ratio convenientiae solutionis.
Vexillum relativum declinationis: NMT 0.73%, Standard solution
Analysis
Exempla: Standard solution et Sample solutionem
Computa recipis C17H14F3N3O2S in partibus Celecoxib desumptis;
Proventus = (rU/rS) (CS/CU) 100
rU = apicem responsio ex Sample solutione
rS = apicem responsio ex solutione Latin
CS = retrahitur solutionis Standard (mg/mL)
CU = retrahitur Sample solutionis (mg/mL)
Criteria acceptationis: 98.0%~ 102.0% in anhydrous basi
IMPURITIES
Inorganic immunditias
• METALS: NMT 20 ppm
Diluent: Acetone et aqua (17:3).
Solutio Standard: Dilutire 1.0 mL Solutio Latin Plumbi, sub Metallis Gravibus praeparata ut fertur <231>, Special Reagentia cum Diluentibus ad 20 mL.
Sample solutio: Dissolve 0,50 g de Celecoxib in 20mL diluentis.
Solutio blank: XX mL de Diluent
Analysis
Exempla: Solutio Standard, solutio blank, solutionis Sample
Ad singulas solutiones adde 2 mL pH 3.5 acetatum Buffer sub Metallis gravia ordinatis praeparatum <231>, Methodum I. Misce, et adde solutioni singulae 1.2 mL thioacetamidei-glycerini basi TS.Misce statim, et permitte stare pro 2 min.Solutiones fac per filtrum magnitudinis 0,45-µm porum.Confer maculas eliquarum ex singulis solutionibus.
Re- gulae acceptationis: Coloris maculae brunneo-nigrae resultans ex solutione Sample non vehementior est quam maculae ex solutione apocrypha resultante.Testis invalidus est si solutio Vulgatae colorem fusco-nigrum solutioni blank comparatum non ostendit.
• RESIDUUM DE IGNITIONE <281>: NMT 0.2%, platinum uasculum adhibito
Impurities organica
• PROCEDUR
Quiddam, Phase mobile, Solutio diluens, Ratio idoneitatis, Solutio Sample et systema chromatographicum: Perge uti in Perge.
Solutio Standard: 0.5 μg/mL USP Celecoxib RS in Diluent
Ratio convenientia
Exempla: Ratio idoneitatis solutionis et solutionis Standardi
Convenientia requisita
Resolutio: NLT 1.8 inter Celecoxib relata compositorum A et Celecoxib et NLT 1.8 inter Celecoxib et Celecoxib relata compositi B, Ratio congruentia solutionis.
Signo-ad-sonitum ratio: NLT 20, Standard solution
Analysis
Exempla: Standard solution et Sample solutionem
Recipis cujuslibet immunditiae in portione Celecoxib sumpto;
Proventus = (rU/rS) (CS/CU) 100
rU = apicem responsio pro qualibet immunditia in solutione Sample
rS = apicem responsionis celecoxib in solutione Standard
CS = retrahitur celecoxib in solutione Standard (mg/mL)
CU = intentio Celecoxibi in solutione Sample (mg/mL)
Criteria acceptatio
Individua immunditia: vide Tabula 1 .
[NOTA-Aliquas immunditiae apicem minus quam 0.05%.]
Table 1
| Nomen | Relativum Retentionis Tempus | Acceptatio Criteria NMT (%) |
| Celecoxib affinis compositis Aa | 0.9 | 0.4 |
| Celecoxib | 1.0 | - |
| Celecoxib affinis compositi Bb | 1.1 | 0.10 |
| Singula immunditia non specificata | - | 0.10 |
| Summa immunditiae | - | 0.5 |
a 4-[5-(3-Methylphenyl) -3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide.
b 4-[3-(4-Methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide.
IN SPECIE TESTS
• AQUA BENEDICTIO, Modus I <921>: NMT 0.5%, usus 400-mg sample
ADDITICIUS REQUISITIS
• PACKAGING AND RECONCILIO: Conserva in vasis strictis, a lumine et humore munito.Copia ad locus temperatus
• USP Reference STANDARDS <11>
USP Celecoxib RS
p.
C17H14F3N3O2S 381.4
USP Celecoxib Related Compone A RS
4-[5-(3-Methylphenyl) -3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide.
C17H14F3N3O2S 381.4
USP Celecoxib Related Compone B RS
4-[3-(4-Methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide.
C17H14F3N3O2S 381.4
Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.
Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.
Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.
Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.
Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.
Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.
MOQ?Nec MOQ.Parvus ordo placet.
Tempus adferendi? Si intus prosapia, tres dies partus praestatur.
Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.
Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.
Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.
Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
| Periculum symbola | Xn - Noxia |
| Periculum Codes | R20/21/22 - Inspiratio noxia, in contactu cum cute et absorpta. |
| R52 - Noxia organismis aquaticis | |
| R61 - Sit partus nocumentum | |
| R60 - May fecunditas imminuat | |
| Salus Descriptio | S22 — Pulverem ne respirare. |
| S24/25 - contactus cum cute et oculis fuge. | |
| S28 - Post contactum cutis, statim lava cum copia saponis suds. | |
| S37/39 - gere idoneam caestus et oculum/faciem praesidio | |
| Consociatione Nationum IDs | UN 3077 9 / PGIII |
| WGK Germania | 3 |
| RTECS | DB2944937 |
| HS Code* | 2935900090 |
| Periculum Classis | INRITATIO |
Celecoxib et Rofecoxib duo inhibitores nunc COX-2 sunt usi.Feliciter evoluta a GD Searle & Pfizer Co. (US,) anno 1999, nomen artis: Celebrex.Celecoxib est agens nonsteroidale, anti-inflammatorium cum effectibus analgesicis et anti-inflammatoriis significantibus, causans infimum tractus ulcerum gastrointestinalium superiorum incidentes et alia inpedimenta.Usus amet ut tractaret osteoarthritis et arthritis et rheumatoideis acutis et longis, cum anti-inflammatione analgesico munere, sublevandis signis et symptomatibus osteoarthritis et arthritis rheumatoideis.
Celecoxib (CAS: 169590-42-5), Ad relevium et administrationem OSTEOARTHRITIS (OA), arthritis rheumatoidei (RA), arthritis rheumatoidis juvenilis (JRA), spondylitis ankylosingis, acutus dolor, prima dysmenorrhea et oralis adiuncti ad curationem aegrotantium solitam. cum familiaribus polyposis adenomatous.
Celecoxib (CAS: 169590-42-5) anti-inflammatorem et analgesicum effectum NSAIDs habet.Propter suam structuram chemicam componi potest cum COX-2, selective inhibito COX-2.Circulus eius phenyl cum alveo hydrophobico COX-2 alligat, eiusque sulfonamide hydrophilicus catenam hydrogenii format cum 513 arginine et 90 histidine in sinum COX-2 ".Etiam arcte cum arginine in positione COX-2120 agit et munere funguntur inhibendo COX-2 ab acido arachidonico in prostaglandinos convertendo, quae corpori humano nocent. Celecoxib in COX-1 moleculum non potest, nec transmutationem arachidonici in prostaglandins inhibere, itaque effectus anti-inflammatorios et analgesicos bonos habet, mucosae gastrici tuetur, sanguinem renum protegit, aggregationem redigit et resolvit. irritatio gastrica problemata NSAIDs communiter adhibita.
Celecoxib (CAS: 169590-42-5) indicatur curatione osteoarthritis et arthritis rheumatoidis.Usus eius in singulis cum hypersensivitate contra sulfonamides vel alias NSAIDs contraindicata est.Caute utendum est in personis cum morbo hepatico.Interationes occurrunt cum aliis medicamentis quae inducunt CYP2C9 (eg rifampin rifampin) vel metabolismi ab hoc enzyme (eg fluconazole, leflunomide).Communes motus adversae in celecoxib sunt mites ad effectus GI moderandos quales sunt dyspepsia, diarrhoea, et dolor abdominis.Gravis GI et renum effectus raro inciderunt.
